| 标题 |
Tezepelumab reduces inflammatory biomarkers as early as week 2 and maintains reductions Until Week 52 in the Phase 3 NAVIGATOR severe asthma trial
|
| 网址 |
求助人暂未提供
|
| DOI |
暂未提供,该求助的时间将会延长,查看原因?
|
| 其它 | Griffiths JM, Pham TH, Wang E.. J Allergy Clin. 2022;149(2):AB14 |
| 求助人 | |
| 下载 | 暂无链接,等待应助者上传 |
PDF的下载单位、IP信息已删除
(2025-6-4)